Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma.

Aging - 17 Aug 2023

Li Liu, Tianrui Kuang, Chunlei Li, Zhendong Qiu, Xiaoyan Chen, Wenhong Deng

Abstract excerpt

BACKGROUND: The advent of immune checkpoint inhibitors (ICIs) has altered the outlook for cancer treatment. The estimation of predictive biomarkers could contribute to maximizing the benefits from ICIs treatment. Here, we explored the association between HYDIN mutations (HYDIN-MUT) in melanoma and ICIs efficacy. METHODS: Clinical data and sequencing data from published studies were utilized to assess the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair
Share to Immune Checkpoint Inhibitors
Share to Melanoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Mutation Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 37595251
DOI: 10.18632/aging.204925
PMCID: PMC10496993

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma.PMID 37595251Read ↗

Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma: Current and Future PerspectivesSemantic proximity Read ↗

RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma.Semantic proximity Read ↗

Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.Semantic proximity Read ↗

Extreme Tumor Mutational Burden Predicts Near-Curative Outcomes With Checkpoint Immunotherapy in Melanoma: Half the Eligible, Half the Cure.Semantic proximity Read ↗

KMT2C is a Potential Biomarker of Anti-PD-1 Treatment Response in Metastatic Melanoma.Semantic proximity Read ↗

Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort.Semantic proximity Read ↗

Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma.Semantic proximity Read ↗

Clinical Impact of Immune Checkpoint Inhibitor (ICI) Response, DNA Damage Repair (DDR) Gene Mutations and Immune-Cell Infiltration in Metastatic Melanoma Subtypes.Semantic proximity Read ↗

Association of EYS mutations with immune checkpoint inhibitor outcome and response in melanoma and non-small cell lung cancerSemantic proximity Read ↗

Homologous recombination repair gene mutations as a predictive biomarker for immunotherapy in patients with advanced melanoma.Semantic proximity Read ↗

Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma.Semantic proximity Read ↗

Predictive value of ZFHX4 mutation for the efficacy of immune checkpoint inhibitors in non-small cell lung cancer and melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.